Annual Secretarial Compliance Report for the year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genpharmasec Limited has filed its Annual Secretarial Compliance Report for FY 2025-26, reviewed by Practicing Company Secretaries M/s. Jaymin Modi & Co. The report covers compliance with multiple SEBI regulations including LODR 2015, ICDR 2018, SAST 2011, and PIT Regulations. All 13 compliance checkpoints—including secretarial standards, policy adoption, website maintenance, director disqualification checks, related party transactions, and insider trading norms—showed full compliance. No deviations, penalties, or actions by SEBI or BSE were recorded during the review period. The company has no material subsidiary and no additional non-compliance was observed.
This clean compliance report indicates the company maintained good governance standards with no regulatory issues. Shareholders can view this as a positive signal regarding the company's adherence to SEBI norms and corporate governance practices, though it does not impact stock price directly.